The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10206 malaria professionals are enjoying the free benefits of MalariaWorld today

chloroquine

NOT Open Access | Case Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase-Deficient Malaria Patient in Southeastern Bangladesh

November 12, 2019 - 16:16 -- NOT Open Access
Author(s): 
Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, Rahmat H, Satyagraha AW, Prue AS, Khan WA, Ley B, Alam MS.
Reference: 
Am J Trop Med Hyg. 2019 Nov 4

We herein report the first case of Mediterranean glucose-6-phosphate dehydrogenase (G6PD) variant from Bangladesh. A boy had been admitted to hospital and was diagnosed with uncomplicated Plasmodium vivax infection and treated with 30 mg/kg body weight (BW) chloroquine for 3 days and 4.8 mg/kg BW primaquine (PQ) to be taken over 14 days.

Country: 
Medical Condition: 
Medical Treatment: 

Antibody Biomarkers Associated with Sterile Protection Induced by Controlled Human Malaria Infection under Chloroquine Prophylaxis

March 6, 2019 - 13:25 -- Open Access
Tags: 
Author(s): 
Joshua M. Obiero, Joseph J. Campo, Philip L. Felgner, et al.
Reference: 
mSphere January/February 2019 4:e00027-19

Immunization with sporozoites under chloroquine chemoprophylaxis (CPS) induces distinctly preerythrocytic and long-lasting sterile protection against homologous controlled human malaria infection (CHMI).

Medical Treatment: 

Lack of significant recovery of chloroquine sensitivity in Plasmodium falciparum parasites following discontinuance of chloroquine use in Papua New Guinea

November 27, 2018 - 15:32 -- Open Access
Author(s): 
Makoto Sekihara, Shin-Ichiro Tachibana, Toshihiro Mita, et al.
Reference: 
Malaria Journal 2018 17:434, 26 November 2018

Eight years of chloroquine withdrawal has not induced a significant recovery of susceptibility in Papua New Guinea.

Medical Treatment: 

Non-falciparum malaria imported mainly from Africa: a review from a Portuguese hospital

July 26, 2017 - 15:52 -- Open Access
Author(s): 
Rogério Ruas, André Pinto, João Nuak, António Sarmento and Cândida Abreu
Reference: 
Malaria Journal 2017 16:298, 25 July 2017

NFM remains an important cause of imported malaria in patients from sub-Saharan Africa, alone or as mixed infection with P. falciparum.

Continent: 
Medical Treatment: 

Genetic diversity and natural selection of Plasmodium vivax multi-drug resistant gene (pvmdr1) in Mesoamerica

July 4, 2017 - 15:36 -- Open Access
Author(s): 
Lilia González-Cerón, Alberto Montoya, Josselin C. Corzo-Gómez, Rene Cerritos, Frida Santillán and Marco A. Sandoval
Reference: 
Malaria Journal 2017 16:261, 1 July 2017

The pvmdr1 gene might have diversified recently at regional level.

Medical Treatment: 

NOT Open Access | Bistacrine derivatives as new potent antimalarials

July 23, 2016 - 17:59 -- NOT Open Access
Author(s): 
Ines Schmidt, Gabriele Pradel, Ludmilla Sologub, Alexandra Golzmann, Che J. Ngwa, Anna Kucharski, Tanja Schirmeister, Ulrike Holzgrabe
Reference: 
Bioorganic & Medicinal Chemistry, Volume 24, Issue 16, 15 August 2016, Pages 3636–3642

Linking two tacrine molecules results in a tremendous increase of activity against Plasmodia in comparison to the monomer.

Medical Treatment: 

Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border

March 1, 2016 - 18:10 -- Open Access
Author(s): 
Richard Höglund, Younis Moussavi, Ronnatrai Ruengweerayut, Anurak Cheomung, Angela Äbelö and Kesara Na-Bangchang
Reference: 
Malaria Journal 2016 15:129, 29 February 2016

The developed population-based pharmacokinetic model could be applied for future prediction of optimal dosage regimen of chloroquine in patients with P. vivax infection.

Medical Treatment: 

Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study

January 29, 2016 - 18:49 -- Open Access
Author(s): 
Neena Valecha, Deepali Savargaonkar, Anupkumar R. Anvikar, et al.
Reference: 
Malaria Journal 2016 15:42, 27 January 2016

The study showed that FDC of arterolane maleate and PQP effectively cured vivax malaria and attained acceptable level of cure up to day 28.

Medical Treatment: 

Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors

October 14, 2015 - 08:47 -- Open Access
Author(s): 
Margarete Gomes, José Vieira, Álvaro D’Almeida Couto, et al.
Reference: 
Malaria Journal 2015, 14:402 (9 October 2015)

In the municipality of Oiapoque, the therapeutic regime used for the treatment of P. vivax malaria using chloroquine combined with primaquine remains effective, when external factors are controlled, such as the quality of anti-malarial drugs, the adhesion to the treatment prescribed, the correct diagnostic and the adjustment of primaquine dose for patient body weight.

Medical Treatment: 

NOT Open Access | A Pantetheinase-Resistant Pantothenamide with Potent, On-Target, and Selective Antiplasmodial Activity

May 18, 2015 - 14:44 -- NOT Open Access
Author(s): 
Cristiano J. Macuamule, Erick T. Tjhin, Collins E. Jana, Leanne Barnard, Lizbé Koekemoer, Marianne de Villiers, Kevin J. Saliba, and Erick Strauss
Reference: 
Antimicrob. Agents Chemother. June 2015 vol. 59 no. 6 3666-3668

Pantothenamides inhibit blood-stage Plasmodium falciparum with potencies (50% inhibitory concentration [IC50], ∼20 nM) similar to that of chloroquine.

Medical Treatment: 

Pages

Subscribe to RSS - chloroquine